Introduction Glucagon-like peptide-1 (GLP-1) analogs, widely used in type 2 diabetes mellitus (T2DM), have shown reduced risks of cardiovascular events, stroke, thrombotic events and all-cause mortality in populations with diabetes and obesity in previous studies [1, 2]
2017 meta-analysis: A systematic review and meta-analysis of nine randomized controlled trials showed that ALCAR supplementation significantly decreased depressive symptoms compared to placebo (standardized mean difference 1.10, 95% CI 1.65 to 0.56), with effects comparable to established antidepressants like fluoxetine, particularly in older adults or those with treatment-resistant depression [5][30]
CBC News reported that Mina Tadrous, an associate professor at the University of Toronto who researches drug policy, said three generics on the market could bring prices down to about $100 or less, depending on dose [Source: cbc.ca/news/health/ozempic-generic-health-canada-9.7180566]
Important safety considerations include an increased risk of hypoglycemia when used with insulin or sulfonylureas, and a boxed warning about thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2)
No commitment to treatment.
